Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Kruit

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
European Journal of Clinical Investigation|April 12, 2000
Intrapleural administration of tumour necrosis factor-alpha (TNFalpha) in patients with mesothelioma: cytokine patterns and acute-phase protein responseT C Stam, A J Swaak, W H Kruit, et al.
British Journal of Cancer|November 21, 1998
Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patientsR de Wit, W H Kruit, G Stoter, et al.
American Journal of Rhinology|January 1, 1997
Effects of a single dose of loratadine on flying ability under conditions of simulated cabin pressureP J Valk, R M Simons, P A Struyvenberg, et al.
Journal of Perinatology : Official Journal of the California Perinatal Association|April 15, 2016
Foley catheter induction of labor as an outpatient procedureH Kruit, O Heikinheimo, V-M Ulander, et al.
Acta Neuropsychiatrica|March 16, 2016
Management of psychiatric adverse events with immunotherapy with interferon-alfaA R Van Gool, W H Kruit, J J Cornelissen, et al.
Journal of the National Cancer Institute|October 2, 1996
Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor supportR de Wit, J Verweij, M Bontenbal, et al.
Breast Cancer Research and Treatment|May 1, 1995
Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancerM Bontenbal, A S Planting, J Verweij, et al.
Cancer Chemotherapy and Pharmacology|July 22, 2009
Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991)Alexander M M Eggermont, Marna G Bouwhuis, Wim H Kruit, et al.
British Journal of Cancer|June 1, 1995
Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanomaW H Kruit, S H Goey, F Calabresi, et al.
British Journal of Cancer|March 25, 2000
Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working PartyC M van Herpen, R L Jansen, W H Kruit, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
European Journal of Clinical Investigation|April 12, 2000
Intrapleural administration of tumour necrosis factor-alpha (TNFalpha) in patients with mesothelioma: cytokine patterns and acute-phase protein responseT C Stam, A J Swaak, W H Kruit, et al.
British Journal of Cancer|November 21, 1998
Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patientsR de Wit, W H Kruit, G Stoter, et al.
American Journal of Rhinology|January 1, 1997
Effects of a single dose of loratadine on flying ability under conditions of simulated cabin pressureP J Valk, R M Simons, P A Struyvenberg, et al.
Journal of Perinatology : Official Journal of the California Perinatal Association|April 15, 2016
Foley catheter induction of labor as an outpatient procedureH Kruit, O Heikinheimo, V-M Ulander, et al.
Acta Neuropsychiatrica|March 16, 2016
Management of psychiatric adverse events with immunotherapy with interferon-alfaA R Van Gool, W H Kruit, J J Cornelissen, et al.
Journal of the National Cancer Institute|October 2, 1996
Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor supportR de Wit, J Verweij, M Bontenbal, et al.
Breast Cancer Research and Treatment|May 1, 1995
Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancerM Bontenbal, A S Planting, J Verweij, et al.
Cancer Chemotherapy and Pharmacology|July 22, 2009
Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991)Alexander M M Eggermont, Marna G Bouwhuis, Wim H Kruit, et al.
British Journal of Cancer|June 1, 1995
Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanomaW H Kruit, S H Goey, F Calabresi, et al.
British Journal of Cancer|March 25, 2000
Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working PartyC M van Herpen, R L Jansen, W H Kruit, et al.
Pageof 4